A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Thyroid hormone and folinic acid in young children with Down syndrome: the phase 3 ACTHYF trial
2019
Genetics in Medicine
To determine whether folinic acid (FA) and thyroxine, in combination or alone, benefit psychomotor development in young patients with Down syndrome (DS). The Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children (ACTHYF) was a single-center, randomized, double-blind, placebo-controlled phase 3 trial in DS infants aged 6-18 months. Patients were randomly assigned to one of four treatments: placebo, folinic acid (FA),
doi:10.1038/s41436-019-0597-8
pmid:31281181
fatcat:ujmq4a5bg5buhihfbrimw4bsp4